OmniAb Reports First Quarter 2023 Financial Results and Business Highlights

EMERYVILLE, Calif.–(BUSINESS WIRE)–OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates. “Our first quarter performance is a strong start to the year. We reached 301 active programs, with 27 in clinical development or approved for commercialization…


ADVERTISEMENT — Advertise With Biotech Networks